Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Castellani

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Translational Gastroenterology and Hepatology|January 23, 2018
Impact of direct-acting antiviral agents on the risk for hepatocellular carcinomaXavier Adhoute, Paul Castellani, Marc Bourlière
World Journal of Hepatology|April 8, 2015
Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?Xavier Adhoute, Guillaume Penaranda, Paul Castellani, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Sofosbuvir as backbone of interferon free treatmentsMarc Bourlière, Valèrie Oules, Christelle Ansaldi, et al.
Therapeutic Advances in Gastroenterology|December 22, 2018
Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?Marc Bourlière, Olivia Pietri, Paul Castellani, et al.
Hepato-Gastroenterology|June 28, 2003
Congenital intrathoracic herniation of the right liver--late presentation as anicteric cholestasisSerge-G Tueche, Jean Hardwigsen, Paul Castellani, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 31, 2013
How to optimize current therapy of HCV genotype 1 infection with boceprevirMarc Bourlière, Xavier Adhoute, Astrid Wendt, et al.
Hepatology (Baltimore, Md.)|January 29, 2008
Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patientPhilippe Colson, Nabil Brouk, Frédérique Lembo, et al.
La Revue Du Praticien|April 2, 2011
[Treatment of hepatitis C]Marc Bourlière, Asma Khaloun, Paul Castellani, et al.
Clinical Pharmacology : Advances and Applications|January 29, 2014
Chronic hepatitis C: future treatmentAstrid Wendt, Xavier Adhoute, Paul Castellani, et al.
Liver Cancer|December 5, 2019
Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective AnalysisJean-Luc Raoul, Xavier Adhoute, Guillaume Penaranda, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Translational Gastroenterology and Hepatology|January 23, 2018
Impact of direct-acting antiviral agents on the risk for hepatocellular carcinomaXavier Adhoute, Paul Castellani, Marc Bourlière
World Journal of Hepatology|April 8, 2015
Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?Xavier Adhoute, Guillaume Penaranda, Paul Castellani, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Sofosbuvir as backbone of interferon free treatmentsMarc Bourlière, Valèrie Oules, Christelle Ansaldi, et al.
Therapeutic Advances in Gastroenterology|December 22, 2018
Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?Marc Bourlière, Olivia Pietri, Paul Castellani, et al.
Hepato-Gastroenterology|June 28, 2003
Congenital intrathoracic herniation of the right liver--late presentation as anicteric cholestasisSerge-G Tueche, Jean Hardwigsen, Paul Castellani, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 31, 2013
How to optimize current therapy of HCV genotype 1 infection with boceprevirMarc Bourlière, Xavier Adhoute, Astrid Wendt, et al.
Hepatology (Baltimore, Md.)|January 29, 2008
Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patientPhilippe Colson, Nabil Brouk, Frédérique Lembo, et al.
La Revue Du Praticien|April 2, 2011
[Treatment of hepatitis C]Marc Bourlière, Asma Khaloun, Paul Castellani, et al.
Clinical Pharmacology : Advances and Applications|January 29, 2014
Chronic hepatitis C: future treatmentAstrid Wendt, Xavier Adhoute, Paul Castellani, et al.
Liver Cancer|December 5, 2019
Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective AnalysisJean-Luc Raoul, Xavier Adhoute, Guillaume Penaranda, et al.
Pageof 4